Peptide Calculator Plus
GLP-1 / Weight Management

Retatrutide Dosage Calculator

A triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. In Phase 3 trials. Early results showed up to 24% body weight loss, making it potentially the most effective weight loss peptide.

Also known as: LY3437943, Triple G

Peptide Reconstitution Calculator

Select a peptide or enter custom values. All calculations are performed locally in your browser.

Retatrutide -- A triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. In Phase 3 trials. Early results showed up...Route: Subcutaneous injection | Frequency: 1x per week | Half-life: ~6 days
Within typical range (500 mcg - 12 mg)

Your Results

Concentration
2.5 mg/mL
= 2500 mcg/mL
Volume to Draw
0.10 mL
Syringe Units (U-100 insulin syringe)
10.0 units
100 units = 1 mL on a standard U-100 insulin syringe
Doses Per Vial
20 doses
at 250 mcg per dose from a 5mg vial
U-100 Insulin Syringe
0u
50u
100u
10.0 units
0.10 mL
Summary: Add 2 mL of bacteriostatic water to your 5mg vial. To get a 250 mcg dose, draw 0.10 mL (10.0 units) on a U-100 insulin syringe. This vial will provide 20 doses at this dosage.
For research purposes only. This calculator is a mathematical tool and does not constitute medical advice. Always consult with a qualified healthcare professional before using any peptide.

Retatrutide Quick Reference

Typical Dose
500 mcg - 12 mg
Frequency
1x per week
Route
Subcutaneous injection
Half-Life
~6 days
Common Vials
5 mg, 10 mg
Reconstituted Stability
Up to 28 days refrigerated
Note: Still in clinical trials. Titration is essential -- start at 0.5 mg/week and increase gradually. The triple agonist mechanism produces stronger weight loss but potentially more GI side effects than dual or single agonists.

Retatrutide Storage

Lyophilized: 2-8 C. Reconstituted: 2-8 C

Stability after reconstitution: Up to 28 days refrigerated. Always use bacteriostatic water for multi-use reconstitution. Label the vial with the reconstitution date and discard after the stability period.

Retatrutide Frequently Asked Questions

Retatrutide (LY3437943) is a triple-receptor agonist that targets GLP-1, GIP, and glucagon receptors. It is currently in Phase 3 clinical trials and has shown up to 24% body weight reduction in early studies.
Based on clinical trial protocols: start at 0.5 mg/week for 4 weeks, increase to 2 mg for 4 weeks, then 4 mg for 4 weeks, then 8 mg for 4 weeks, and finally 12 mg for maintenance.
Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) while tirzepatide is a dual agonist (GLP-1 + GIP). The added glucagon receptor activity may provide additional metabolic benefits including enhanced fat oxidation.
Add 2 mL bacteriostatic water for 2.5 mg/mL. For 0.5 mg, draw 0.2 mL (20 units). For 2 mg, draw 0.8 mL (80 units).
As of 2024, retatrutide is NOT FDA approved. It is in Phase 3 clinical trials conducted by Eli Lilly. Approval timeline is estimated for 2025-2026 pending trial results.
Similar to other GLP-1 agonists: nausea, diarrhea, vomiting, and decreased appetite. The triple mechanism may intensify GI effects compared to single or dual agonists, making slow titration essential.

Other Peptide Calculators

BPC-157

250 mcg - 500 mcg | 1-2x daily

TB-500

2 mg - 5 mg | 2x per week (loading), 1x per week (maintenance)

Semaglutide

250 mcg - 2.40 mg | 1x per week

Tirzepatide

2.50 mg - 15 mg | 1x per week

CJC-1295 (with DAC)

1 mg - 2 mg | 1-2x per week

CJC-1295 (no DAC) / Mod GRF 1-29

100 mcg - 300 mcg | 2-3x daily

Ipamorelin

200 mcg - 300 mcg | 2-3x daily

PT-141 (Bremelanotide)

1 mg - 2 mg | As needed (max 1x per 24 hours)

Melanotan II

250 mcg - 1 mg | 1x daily (loading), then maintenance